Funding for this research was provided by:
Ministry of Health, Labour and Welfare (28-16)
Received: 13 October 2018
Accepted: 5 March 2019
First Online: 12 March 2019
Ethics approval and consent to participate
: All procedures conformed to the Declaration of Helsinki. This study was approved by the Institutional Review Board of Kumamoto University. Written informed consent was not obtained due to the retrospective manner of the study. Alternatively, this study was carried out by the opt-out method of our department website.
: Not Applicable.
: Dr. Takahashi has received research funding from Novartis Pharma and Bayer Yakuhin. Dr. Tanihara has received consulting fees from Kowa, and MSD, board membership fees from Senju Pharmaceutical, Santen Pharmaceutical, Alcon Japan, and Pfizer Japan, and research grant from Kowa, Senju Pharmaceutical, Santen Pharmaceutical, Alcon Japan, Pfizer Japan, and Otsuka Pharmaceutical. Dr. Inoue has received research grant from Novartis Pharma. Other authors have no financial interest.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.